This article is more than 5 years old. Information may no longer be current.
Weill Cornell Medicine/NewYork-Presbyterian neuro-oncologist receives NIH’s Pioneer Award
Click Here to Manage Email Alerts
Howard A. Fine, MD, received a 5-year, $6 million NIH Director’s Pioneer Award for brain cancer research.
Fine — an internationally recognized neuro-oncologist — is founding director of the Brain Tumor Center and chief of the division of neuro-oncology at Weill Cornell Medicine and NewYork-Presbyterian.
The NIH Director’s Pioneer Awards are presented to investigators who demonstrate exceptional creativity and pursue a bold research strategy to overcome a major biomedical challenge.
Fine will use his award to further his efforts to model brain cancers in the laboratory, which could help lay the foundation for the development of more effective therapies.
“I’m thrilled and honored to have been selected for this award,” Fine said in a press release. “This Pioneer Award will allow us to pursue a brain cancer modeling strategy that represents a bold departure from traditional approaches, which may lead to consequential scientific advances for our patients: new and more effective treatments and therapies. Our work exemplifies the spirit of the NIH’s commitment to high-risk, high-reward research, and I am deeply grateful for this opportunity.”
This is the first Pioneer Award received by Weill Cornell Medicine.
“We are tremendously excited for Dr. Fine for receiving this wonderful accolade, which reflects his accomplishments as a neuro-oncologist and translational scientist,” Augustine M.K. Choi, MD, Stephen and Suzanne Weiss dean of Weill Cornell Medicine, said in the release. “Brain cancer is one of the most devastating diseases, and with Dr. Fine’s innovative approach to understanding how these tumors develop and spread, I have no doubt we can make a difference in our patients’ lives.”